FATE THERAPEUTICS INC Diluted Shares Outstanding (Weighted Average)
FATE THERAPEUTICS INC (FATE) reported Diluted Shares Outstanding (Weighted Average) of 120.40 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-13
- FATE THERAPEUTICS INC weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 120.40M shares, a 1.58% increase year-over-year.
- FATE THERAPEUTICS INC weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 120.03M shares, a 1.40% increase year-over-year.
- FATE THERAPEUTICS INC weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 119.25M shares, a 1.21% increase year-over-year.
- FATE THERAPEUTICS INC weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 119.00M shares, a 1.04% increase year-over-year.
- FATE THERAPEUTICS INC weighted average number of shares outstanding, diluted for fiscal 2025 was 118.79M shares, a 4.49% increase from fiscal 2024.
- FATE THERAPEUTICS INC weighted average number of shares outstanding, diluted for fiscal 2024 was 113.69M shares, a 15.52% increase from fiscal 2023.
- FATE THERAPEUTICS INC weighted average number of shares outstanding, diluted for fiscal 2023 was 98.41M shares, a 1.64% increase from fiscal 2022.
- FATE THERAPEUTICS INC weighted average number of shares outstanding, diluted for fiscal 2022 was 96.83M shares, a 2.19% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 120.40M shares 10-Q · filed 2026-08-13 | 120.22M shares 10-Q · filed 2026-08-13 | 119.89M shares derived: average of 3 quarters · filed 2026-08-13 | 119.67M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 120.03M shares 10-Q · filed 2026-05-13 | 119.64M shares derived: average of 2 quarters · filed 2026-05-13 | 119.43M shares derived: average of 3 quarters · filed 2026-05-13 | 119.20M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | 119.25M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 119.12M shares derived: average of 2 quarters · filed 2026-02-26 | 118.93M shares derived: average of 3 quarters · filed 2026-08-13 | 118.79M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 119.00M shares 10-Q · filed 2025-11-13 | 118.76M shares derived: average of 2 quarters · filed 2026-08-13 | 118.64M shares 10-Q · filed 2025-11-13 | 118.43M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | 118.53M shares 10-Q · filed 2026-08-13 | 118.45M shares 10-Q · filed 2026-08-13 | 118.24M shares derived: average of 3 quarters · filed 2026-08-13 | 118.12M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | 118.38M shares 10-Q · filed 2026-05-13 | 118.10M shares derived: average of 2 quarters · filed 2026-05-13 | 117.99M shares derived: average of 3 quarters · filed 2026-05-13 | 117.86M shares derived: average of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | 117.82M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 117.80M shares derived: average of 2 quarters · filed 2026-02-26 | 117.69M shares derived: average of 3 quarters · filed 2026-02-26 | 113.69M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 117.77M shares 10-Q · filed 2025-11-13 | 117.62M shares derived: average of 2 quarters · filed 2025-11-13 | 112.31M shares 10-Q · filed 2025-11-13 | 108.74M shares derived: average of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | 117.47M shares 10-Q · filed 2025-08-12 | 109.29M shares 10-Q · filed 2025-08-12 | 105.73M shares derived: average of 3 quarters · filed 2025-08-12 | 103.94M shares derived: average of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | 101.10M shares 10-Q · filed 2025-05-13 | 99.86M shares derived: average of 2 quarters · filed 2025-05-13 | 99.43M shares derived: average of 3 quarters · filed 2025-05-13 | 99.17M shares derived: average of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | 98.62M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | 98.59M shares derived: average of 2 quarters · filed 2025-03-05 | 98.53M shares derived: average of 3 quarters · filed 2025-03-05 | 98.41M shares 10-K · filed 2025-03-05 |
| 2023-09-30 | 98.57M shares 10-Q · filed 2024-11-12 | 98.48M shares derived: average of 2 quarters · filed 2024-11-12 | 98.34M shares 10-Q · filed 2024-11-12 | 98.06M shares derived: average of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | 98.40M shares 10-Q · filed 2024-08-13 | 98.23M shares 10-Q · filed 2024-08-13 | 97.89M shares derived: average of 3 quarters · filed 2024-08-13 | 97.68M shares derived: average of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | 98.05M shares 10-Q · filed 2024-05-09 | 97.64M shares derived: average of 2 quarters · filed 2024-05-09 | 97.43M shares derived: average of 3 quarters · filed 2024-05-09 | 97.25M shares derived: average of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | 97.23M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | 97.12M shares derived: average of 2 quarters · filed 2024-02-26 | 96.98M shares derived: average of 3 quarters · filed 2024-02-26 | 96.83M shares 10-K · filed 2024-02-26 |
| 2022-09-30 | 97.02M shares 10-Q · filed 2023-11-08 | 96.86M shares derived: average of 2 quarters · filed 2023-11-08 | 96.69M shares 10-Q · filed 2023-11-08 | 96.47M shares derived: average of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | 96.70M shares 10-Q · filed 2023-08-08 | 96.52M shares 10-Q · filed 2023-08-08 | 96.28M shares derived: average of 3 quarters · filed 2023-08-08 | 96.06M shares derived: average of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | 96.34M shares 10-Q · filed 2023-05-03 | 96.07M shares derived: average of 2 quarters · filed 2023-05-03 | 95.85M shares derived: average of 3 quarters · filed 2023-05-03 | 95.47M shares derived: average of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | 95.80M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 95.60M shares derived: average of 2 quarters · filed 2023-02-28 | 95.18M shares derived: average of 3 quarters · filed 2023-02-28 | 94.75M shares 10-K · filed 2023-02-28 |
| 2021-09-30 | 95.41M shares 10-Q · filed 2022-11-03 | 94.87M shares derived: average of 2 quarters · filed 2022-11-03 | 94.40M shares 10-Q · filed 2022-11-03 | |
| 2021-06-30 | 94.33M shares 10-Q · filed 2022-08-03 | 93.88M shares 10-Q · filed 2022-08-03 | ||
| 2020-12-31 | 82.39M shares 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |